Remlife Global PTE LTD, a Singapore-based subsidiary of Remedium Lifecare Ltd. (BSE-listed), is excited to announce a strategic partnership with JiyaYu Lifesciences PTE Ltd., a leading green chemistry technology platform. This collaboration is focused on replacing animal-derived raw materials in the production of active pharmaceutical ingredients (APIs) and advanced intermediates with sustainable, scalable alternatives using proprietary fermentation and biocatalyst-based technologies.

Under the agreement, JiyaYu will exclusively license its fully developed and scalable technologies to Remlife Global. These technologies aim to replace traditional animal-derived processes with eco-friendly, cost-effective, and regulatory-compliant bioprocesses. Remlife Global will be responsible for scaling up and commercializing these solutions across multiple GMP-compliant manufacturing sites in India, Singapore, Malta, Ireland, Belgium, and Italy.

JiyaYu has partnered with a UK-based R&D technology platform that specializes in developing fermentation and biocatalyst-based alternatives to animal-origin pharmaceutical inputs. This collaboration grants JiyaYu access to cutting-edge innovations that will be transferred to Remlife Global as fully scalable technologies.

Each technology transfer will be accompanied by detailed process documentation, enabling Remlife Global to implement, validate, and scale these solutions at approved GMP manufacturing sites.

This partnership supports Remlife Global’s vision of eliminating reliance on ethically complex and vulnerable supply chains, while creating new commercial opportunities in global regulated markets.

Adarsh Munjal, CEO of Remlife Global, commented, “Our collaboration with JiyaYu Lifesciences is a transformative step towards building a more ethical, resilient, and sustainable pharmaceutical supply chain.”